Maximising impact of research in neurodevelopmental disorders (MINDDS)
Mae'r cynnwys hwn ar gael yn Saesneg yn unig.
MINDDS is a pan-European partnership between researchers, clinicians and patient organisations to facilitate research on Neurodevelopmental disorders (NDD) associated with pathogenic Copy Number Variants (CNV).
It focuses on the development of improved patient identification and assessment, standardisation of research protocols and guidelines and methodologies for data deposition, sharing and analysis.
Understanding rare neurodevelopmental disorders has the potential to drive major new therapies for more common neuropsychiatric disorders such as schizophrenia and Autism Spectrum Disorder.
NDD affect 1 in 25 individuals and have a high impact on healthcare systems, economic development and society. The key challenge is to link new knowledge from psychiatric genomics to identify neurobiological mechanisms that lead to NDD.
MINDDS focuses on patients with rare pathogenic CNV. MINDDS aims to substantially accelerate NDD research progress via a Europe-wide collaborative network to identify individuals who possess pathogenic CNV, agree standardized assessments and research protocols and facilitate data sharing and knowledge exchange for the benefit of researchers, clinicians and patients.
For more information regarding joining MINDDS, please contact: